GILD vs PFE — Key Metrics

Metric GILD (GILEAD SCIENCES INC) PFE (PFIZER INC)
Price168.9828.06
Market Cap209.59 Billion159.94 Billion
P/E (TTM)-54.5139.52
P/B (Quarterly)16.2351.921
P/S (TTM)6.762.51
Net Profit Margin (TTM)-12.56.3
Gross Margin (TTM)79.973.4
ROE (TTM)-21.74.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

GILEAD SCIENCES INC
vs
 
PFIZER INC
 
GILEAD SCIENCES INC
vs
 
PFIZER INC
Performance Comparison
AI Model Recommendation
GILD · GILEAD SCIENCES INC

Outperform

57
UnderperformOutperform
PFE · PFIZER INC

Greatly Outperform

91
UnderperformOutperform
Recommendation Summary

Stock GILD is projected to outperform the market, stock PFE is projected to greatly outperform the market. Upfront Recommendation: PFE.

Financial Metrics
Prices delayed ~15 min
GILD Metrics PFE
$168.98 Price $28.06
— Market Capitalization —
6.76 Price to Sales 2.51
15.21 Price to FCF Ratio 13.57
8.46 Price to Gross Profit 3.43
33.12 Price to R&D 13.88
12.66 Price to Current Assets 3.55

GILD vs PFE at a glance

Gilead Sciences INC (GILD) and Pfizer INC (PFE) are both Drug Manufacturers - General companies in the Healthcare sector. GILD is the larger, at $209.6 billion in market value against $159.9 billion for PFE, about 1.3 times the size.

On trailing-twelve-month figures, GILD trades at 6.8 times trailing sales and PFE at 2.5; net profit margins are -12.5% and 6.3%.

The Upfront Investment model currently rates GILD Outperform and PFE Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.